NCT06752798View on ClinicalTrials.gov

Bone Marrow Protective Effect of Trilaciclib in Postoperative CCRT for LA-HNSCC

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 30, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

December 30, 2025

Conditions
Head and Neck Cancer Squamous Cell Carcinoma
Interventions
DRUG

Trilaciclib + Cisplatin

Trilaciclib: 240 mg/m², intravenous infusion over 30 minutes, administered within 4 hours prior to each chemotherapy session. Cisplatin: 40 mg/m², intravenous infusion over 2-3 hours, once a week, for a total of 6-7 times.

Trial Locations (1)

410000

RECRUITING

Hunan Cancer hospital, Changsha

All Listed Sponsors
lead

Hunan Cancer Hospital

OTHER